Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream
that might represent an important biomarker in lung cancer. The prognosis of patients …

Introduction In recent years, immunotherapy has become a pillar in the treatment of advanced,
non-oncogene-addicted non-small cell lung cancer (NSCLC). Programmed death ligand …

Simple Summary Immune checkpoint blockade (ICB) with antibodies targeting CTLA-4 (Cytotoxic
Lymphocyte Antigen 4) and/or programmed death-1 protein (PD-1)/programmed death …

Background Rare cases of severe myocarditis are reported during treatment with nivolumab.
Troponin, a biomarker of cardiac damage, is a key component of the diagnostic workup of …

The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the
advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy …

This study assesses the impact of COVID‐19 on household consumption poverty. To predict
changes in income and the associated effects on poverty, we rely on existing estimated …

We aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma
cell–free DNA (cfDNA) on one side and a comprehensive range of 18 F-FDG PET/CT–derived …

Non-small cell lung cancer (NSCLC) is one of the most common causes of cancer-related
death worldwide. Based on the patient’s stage of disease, treatment options include surgery, …

PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH)
and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. …

Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and
predictive biomarkers in non-small cell lung cancer (NSCLC). In this study, we examined the …